12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $549M | $457M | 38.7% | -7.1% | -$79M | $118M | $71M |
| 2024 | $630M | $38M | 44.6% | -6.9% | -$17M | $106M | $154M |
| 2023 | $838M | $101M | 54.1% | 2.2% | $187M | $110M | $284M |
| 2022 | $426M | -$361M | 27.0% | -95.6% | -$305M | $18M | $313M |
| 2021 | $356M | -$195M | 0.0% | -92.2% | -$221M | $27M | $378M |
| 2020 | $228M | -$126M | 0.0% | -86.3% | -$70M | $27M | $236M |
| 2019 | $205M | -$106M | 0.0% | -71.4% | -$89M | $27M | $121M |
| 2018 | $214M | -$75M | 0.0% | -43.3% | -$39M | $27M | $86M |
| 2017 | $241M | -$27M | 0.0% | -22.1% | -$14M | $30M | $85M |
| 2016 | $216M | $12M | 0.0% | -21.6% | -$14M | $47M | $79M |
| 2015 | — | $8M | — | — | -$13M | $50M | $32M |
| 2014 | — | -$7M | — | — | $5M | — | $39M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Dec '19 | $53M | -$30M | 0.0% | -72.0% | -$20M | $27M | $121M |
| Sep '19 | $49M | -$31M | 0.0% | -72.8% | -$35M | $0 | $97M |
| Jun '19 | $50M | -$25M | 0.0% | -71.9% | -$4M | $0 | $83M |
| Mar '19 | $52M | -$20M | 0.0% | -69.1% | -$30M | $27M | $92M |
| Dec '18 | $53M | -$17M | 0.0% | -45.5% | -$17M | $27M | $86M |
| Sep '18 | $59M | -$26M | 0.0% | -25.1% | -$2M | — | — |
| Jun '18 | $50M | -$21M | 0.0% | -57.5% | $11M | $27M | $75M |
| Mar '18 | $52M | -$12M | 0.0% | -47.8% | -$32M | — | — |
How the market has priced HCM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, HUTCHMED (China) Ltd's revenue has grown 19.2% per year. These are computed facts, not advice.
As of FY2025, HUTCHMED (China) Ltd reported $118M of total debt against $71M of cash; operating income covered interest expense -13.7×.
In FY2025, gross margin was 38.7%, operating margin -7.1%, and net margin 83.3%.
As of Jun '26, HUTCHMED (China) Ltd traded at a price-to-earnings ratio of about 19.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.